Name: Cholic acid
Brand: Selleck Chemicals
SKU: S3742
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: S374201 DMSO]81 mg/mL]false]Ethanol]28 mg/mL]false]Water]Insoluble]false Purity: 98.58%

Cited in Nature Medicine for its top-tier quality
COA
SDS/MSDS
Datasheet

98.58

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Others Inhibitors	Furimazine (PBI 3939) Guanidinoacetic acid Blebbistatin Polybrene (Hexadimethrine Bromide) Silibinin (NSC 651520) Palmitic acid Carbazochrome sodium sulfonate (AC-17) 4-Methylumbelliferone (4-MU) Sesamin Osthole

Solubility

In vitro
Batch:

DMSO : 81 mg/mL (198.25 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 28 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.05mg/ml (9.91mM)	Taking the 1 mL working solution as an example, add 50 μL of 81 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.58mg/ml (1.42mM)	Taking the 1 mL working solution as an example, add 50 μL of 11.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	408.57	Formula	C₂₄H₄₀O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	81-25-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Fosfomycin is known to inhibit MurA by covalently binding to a highly conserved cysteine in the active site of the enzyme. Fosfomycin is a PEP mimetic that acts by alkylating the highly conserved Cys115 (Escherichia coli numbering) of MurA. Fosfomycin exerts immunomodulatory effects by altering lymphocyte, monocyte and neutrophil function. It affects the acute inflammatory cytokine response in vitro and in vivo. It suppresses production of tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), and IL-1α and increases production of IL-10. Fosfomycin suppresses IL-2 production from T cells, the production of leukotriene B4 (LTB4) from neutrophils, and the expression of IL-8 mRNA by LTB4 from monocytes. Fosfomycin also exhibits an immunomodulatory effect on B-cell activation. Fosfomycin enhances neutrophil phagocytic killing of invading pathogens, even in patients on chronic hemodialysis and renal transplantation. Fosfomycin resulted in enhanced bactericidal ability of neutrophils compared to other antimicrobials. Fosfomycin has the ability to penetrate into biofilms. fosfomycin is considerably active against both Gram-negative and Gram-positive pathogens.
In vivo	The oral bioavailability of fosfomycin trometamol ranges between 34 and 58%. Absorption occurs in the small intestine, and evidence suggests that coadministration of fosfomycin trometamol with food may reduce absorption of the drug.The mean serum elimination half-life (t1/2) of fosfomycin trometamol is estimated at 5.7 h. Fosfomycin is excreted nonmetabolized in the urine, through glomerular filtration. Depending on age, fasting, and renal function, 11 to 60% of the drug can be found in the urine within 24 h from administration. Specifically, older age, administration with a meal, and deteriorating renal function result in slower elimination through the kidneys. Fosfomycin crosses the blood-brain barrier, and meningeal inflammation increases its concentration in the CSF. Fosfomycin also penetrates in both cortical and cancellous bone, and penetration correlates with plasma levels and the presence of inflammation.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22505403/ [2] http://cmr.asm.org/content/29/2/321.full

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-08)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06755541	RECRUITING	Primary Biliary Cholangitis (PBC)	Xijing Hospital of Digestive Diseases	2024-01-30	PHASE3
NCT07296458	RECRUITING	Primary Biliary Cholangitis (PBC)	Xijing Hospital of Digestive Diseases	2025-12-15	PHASE3
NCT06842472	NOT_YET_RECRUITING	Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2025-02	PHASE2
NCT07378761	NOT_YET_RECRUITING	Immune-Mediated Cholestasis	University Hospital, Montpellier	2026-12	PHASE2
NCT07717242	RECRUITING	Bladder Urothelial Carcinoma; Bladder Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2026-07-01	PHASE2
NCT06591468	ENROLLING_BY_INVITATION	Primary Biliary Cholangitis (PBC)	Han Ying	2024-10-30	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Cholic acid

Chemical Structure

Molecular Weight: 408.57